BioCentury | Mar 27, 2018
Distillery Therapeutics

Cancer

...INDICATION: Cancer; lymphoma; solid tumors Cell culture and mouse studies suggest inhibiting RALBP1 could help treat...
...three subtypes of breast cancer, an antisense oligonucleotide (ASO) targeting RALBP1 and an siRNA targeting RALBP1...
...Next steps could include testing RALBP1 inhibitors in animal models of cancer. TARGET/MARKER/PATHWAY: ralA binding protein 1 (RALBP1; RLIP76...
BioCentury | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Programmed cell death 1 (PD-1; PDCD1; CD279); asparagine-linked glycosylation 8 (ALG8); laminin α subunit 4 (LAMA4); ADP-dependent glucokinase (AD

...laminin α subunit 4 (LAMA4); ADP-dependent glucokinase (ADPGK) ; dolichyl-phosphate UDP-N-acetylglucosamine N-acetylglucosaminephosphotransferase 1 (DPAGT1) ; RALBP1...
BioCentury | Jan 29, 2015
Targets & Mechanisms

Personalized tumor vaccines

...class II PD-1 - ( PDCD1 ; CD279 ) Programmed cell death 1 REPS1 - RALBP1...
BioCentury | Jan 6, 2014
Company News

Merganser Biotech, Terapio, National Institutes of Health, University of North Carolina hematology, neurology, other news

..."hit a roadblock and need additional expertise" to reach the clinic. The projects include developing RLIP76-LyoPL...
...longer after radiation exposure. RLIP76-LyoPL consists of the membrane-associated transport protein ralA binding protein 1 ( RALBP1 ; RLIP76...
Items per page:
1 - 4 of 4